Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 September 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Best direct-acting antiviral regimen for patients with Hep C virus genotype 3 

This month's issue of Clinical Gastroenterology & Hepatology identifies the best direct-acting antiviral regimen for patients with Hepatitis C virus genotype 3 infection.

News image

Direct-acting antivirals are effective in the treatment of chronic hepatitis C virus (HCV) infection, although results for patients infected with genotype 3 are suboptimal. 

There are several regimens available, however, direct comparisons have not been made and are unlikely to occur. 

Dr Joost Drenth and colleagues from the Netherlands identified the most effective direct-acting antivirals regimen for patients infected with HCV genotype 3, and assessed the role of ribavirin.

The researchers conducted a systematic search of PubMed, Embase, and Web of Science databases through 2016. 

Ribavirin increases efficacy in patients with and without cirrhosis
Clinical Gastroenterology & Hepatology
The team performed a Bayesian network meta-analysis using a random-effects model to indirectly compare regimens in patients with and without cirrhosis. 

The researchers identified 2167 articles, of which 27 studies comprizing 3415 patients were included. 

Among patients without cirrhosis, the team found that the greatest rates of sustained virilogic response were estimated for those receiving sofosbuvir + velpatasvir with ribavirin; and without ribavirin; sofosbuvir + daclatasvir + ribavirin; and sofosbuvir + peginterferon + ribavirin, all for 12 weeks. 

Among patients with cirrhosis, the highest rates of sustained virologic response were estimated for those receiving sofosbuvir + velpatasvir for 24 weeks; sofosbuvir + daclatasvir + ribavirin for 24 weeks; and sofosbuvir + velpatasvir + ribavirin for 12 weeks. 

The team observed that ribavirin increases efficacy in patients with and without cirrhosis.

Dr Drenth's team concludes, "An indirect comparison of DAA-based treatments, using Bayesian network meta-analysis, found regimens containing sofosbuvir and velpatasvir to be the best option for patients with HCV genotype 3 infection."

"Our analyses indicated that ribavirin significantly increases sustained virilogical response rates and should be considered if tolerated."

Clin Gastroenterol Hepatol 2017: 15(3): 349–359
09 March 2017

Go to top of page Email this page Email this page to a colleague

 22 September 2017 
MRI for liver metastatic colorectal cancer
 22 September 2017 
Perforation after colonic endoscopic mucosal resection
 22 September 2017 
Medical management and colectomy rates
 21 September 2017 
Predicting mucosal healing in treated celiac disease patients
 21 September 2017 
Antireflux surgery and recurrence of GERD
 21 September 2017 
Adenomatous colorectal polyps in young cancer survivors
 20 September 2017 
Rifaximin and spontaneous bacterial peritonitis in cirrhosis
 20 September 2017 
Omega-3 PUFA and colorectal cancer survival
 20 September 2017 
Beta-blockers and cardiopulmonary exercise testing in liver disease
 19 September 2017 
Birth outcomes in children fathered by men treated with azathioprine
 19 September 2017 
Risk of death and statins in alcoholic cirrhosis
 19 September 2017 
Hospital-readmission risk
 18 September 2017 
Ethnic disparities and Hep C survival
 18 September 2017 
Depression and celiac disease in the USA
 18 September 2017 
Health care services in IBD
 15 September 2017 
Hemidesmosome integrity and colorectal cancer
 15 September 2017 
Herpes zoster vaccination in IBD
 15 September 2017 
Chronic pancreatitis and pancreatic cancer risk
 14 September 2017 
National survey on stopping PPIs
 14 September 2017 
Psychological impact of IBD
 14 September 2017 
Bile tree pathology in patients presenting with gallbladder disease
 13 September 2017 
Predicting clinical outcome in colorectal cancer
 13 September 2017 
Oral contraceptives increases the risk of IBD
 13 September 2017 
Mortality in cirrhosis
 12 September 2017 
Genetic factors and tobacco in IBD
 12 September 2017 
Predictors of colectomy in ulcerative colitis
 12 September 2017 
Low birthweight and pediatric NAFLD
 11 September 2017 
Proteomic analysis of IBD
 11 September 2017 
New therapies to manage Hep B
 11 September 2017 
Ethnic disparities for chronic Hep C survival
 08 September 2017 
Antibiotics and diverticulitis
 08 September 2017 
Improving adherence to colorectal cancer screening
 08 September 2017 
Preoperative workup for colorectal cancer
 07 September 2017 
Laparoscopic surgery use in Medicare patients with colon cancer
 07 September 2017 
Outreach to improve colorectal cancer screening
 07 September 2017 
Nicotine chewing gum after colorectal surgery
 06 September 2017 
Novel candidate risk genes for IBD
 06 September 2017 
PPI use and chronic kidney disease
 06 September 2017 
Colorectal cancer surgery in the very elderly patient
 05 September 2017 
Unprovoked Venous Thromboembolism and occult cancer
 05 September 2017 
Hep E seroprevalence and hemodialysis
 05 September 2017 
Antibody tests and detecting celiac disease
 04 September 2017 
Acute pancreatitis and health related quality of life
 04 September 2017 
Infliximab treatment and eHealth in IBD
 04 September 2017 
Contrast-enhanced ultrasound for diagnosis of liver cancer
 01 September 2017 
Late recurrence of Barrett’s esophagus after eradication
 01 September 2017 
Thalidomide ine children with IBD
 01 September 2017 
Occult cancer screening with unprovoked venous thromboembolism
 31 August 2017 
Asthma and IBD development
 31 August 2017 
Environmental factors and IBD
 31 August 2017 
Management of noncardiac chest pain
 30 August 2017 
Diet and increased flares in patients with ulcerative colitis in remission
 30 August 2017 
Induction of remission in pediatric Crohn's disease
 29 August 2017 
Reducing antibody formation against TNF antagonists in IBD
 29 August 2017 
Epidemiological changes of chronic hepatitis
 28 August 2017 
Hyperuricemia and NAFLD activity score
 28 August 2017 
Therapy for acute variceal hemorrhage
 28 August 2017 
Colectomy rates in ulcerative colitis
 25 August 2017 
Making personalized nutrition a reality
 25 August 2017 
Predicting advanced colorectal cancer survival

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us